- Home
- MIRM vs MBLY Comparison
MIRM vs MBLY Comparison
Compare MIRM & MBLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRM | MBLY |
|---|---|---|
| Founded | 2018 | 1999 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 7.3B |
| IPO Year | 2019 | 2022 |
Fundamental Metrics
Financial Performance| Metric | MIRM | MBLY |
|---|---|---|
| Price | $84.87 | $6.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 24 |
| Target Price | ★ $153.43 | $11.11 |
| AVG Volume (30 Days) | 696.6K | ★ 5.4M |
| Earning Date | 11-10-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 74.59 | ★ 87.43 |
| EPS | N/A | ★ N/A |
| Revenue | $19,138,000.00 | ★ $1,894,000,000.00 |
| Revenue This Year | $33.91 | $5.97 |
| Revenue Next Year | $17.40 | $9.36 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 14.51 |
| 52 Week Low | $63.23 | $6.40 |
| 52 Week High | $130.00 | $14.33 |
Technical Indicators
Market Signals| Indicator | MIRM | MBLY |
|---|---|---|
| Relative Strength Index (RSI) | 48.71 | 40.70 |
| Support Level | $78.07 | $6.63 |
| Resistance Level | $88.31 | $7.60 |
| Average True Range (ATR) | 3.72 | 0.34 |
| MACD | 0.80 | -0.01 |
| Stochastic Oscillator | 66.21 | 38.75 |
Price Performance
Historical ComparisonAbout MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
About MBLY Mobileye Global Inc.
Mobileye Global Inc engages in the development and deployment of ADAS and autonomous driving technologies and solutions. It is building a portfolio of end-to-end ADAS and autonomous driving solutions to provide the capabilities needed for the future of autonomous driving, leveraging a comprehensive suite of purpose-built software and hardware technologies. The company's reportable operating segment are Mobileye and Moovit. The solutions provided by the company are: Driver Assist, Cloud-Enhanced Driver Assist, Mobileye SuperVision Lite, Mobileye SuperVision, Mobileye Chauffeur, Mobileye Drive, Self-Driving System & Vehicles. It derives maximum revenue from Mobileye Segment.